Efficacy of risperidone treatment in Smith-Magenis syndrome (del 17 pll. 2).
Smith-Magenis syndrome (SMS) is a clinically recognizable multiple congenital anomaly and mental retardation syndrome caused by an interstitial deletion of chromosome 17 pll.2. Although the physical and molecular genetic features of SMS are increasingly well understood, work is more limited on SMS's behavioral phenotype, which includes self-injury, tantrums, aggression, attention deficit, and sleep disturbance. This case-report describes the lowering of the aggression level of a 13 year old individual with SMS.
Niederhofer
Helmut
H
Regional Hospital of Bolzano, Department of Pediatrics, Via L.-Boehler, 5, 39100 Bolzano, Italy. helmut.niederhofer@asbz.it
D000015:Abnormalities, Multiple / Q000188:drug therapy* / Q000235:genetics; D000293:Adolescent; D000374:Aggression / Q000187:drug effects; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000235:genetics; D002648:Child; D002872:Chromosome Deletion; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use*; D013577:Syndrome
D014150:Antipsychotic Agents; D018967:Risperidone